# The Healthcare Pulse: April 17–24, 2026

> Podcast-sourced healthcare brief for April 17–24, 2026. UnitedHealth's Q1 beat and a ripping biotech tape meet a widening payer/provider split, an acrimonious bull/bear fight over Eli Lilly, and Merck's LITESPARK-012 pipeline miss.


## The Healthcare Pulse: Weekly Podcast Intelligence Brief

### Week of April 17 – April 24, 2026

---

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 1. This Week at a Glance

Healthcare's week was dominated by two blockbuster stories: **UnitedHealth's Q1 2026 beat** (EPS $7.23 vs. $6.61 consensus, MCR collapsing from ~89% to 83.9%) and the **biotech tape ripping to post-pandemic highs** with XBI attracting "generalist" money and Kailera's $625M+ IPO re-opening the funding window. Running underneath: a widening schism between managed care (DOJ investigations, CMS rate pressure) and providers (HCA/THC/DVA earnings strength), an increasingly acrimonious bull/bear fight over **Eli Lilly** into its April 30 print, and a sudden pipeline whiplash as **Merck's Phase 3 LITESPARK-012 renal cancer study missed on both primary endpoints**.

---

## 2. The People Driving the Conversation

**Stephen Hemsley, UNH CEO** framed Q1 results around a cultural reset: "We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity" (April 21, 2026). His comp package is the story: a cliff-vesting stock option grant with **no annual bonus**. "He only gets paid out if the company's stock hits specific long-term recovery targets down the road. If the multi-year AI pivot fails, he gets nothing." ([Deep Values, April 22, 2026](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f))

**David Wainer, Wall Street Journal** offered the structural critique of the managed care model: "For decades, making money in Medicare Advantage was done by signing up seniors and documenting as many diagnoses as possible, with UnitedHealth one of the industry's most-aggressive coders. As the government works to rein in aggressive coding and begins paying less, this will hit both the insurer and the provider." ([WSJ, April 17, 2026](https://www.wsj.com/health/healthcare/a-unitedhealth-reckoning-still-looms-0f094b9b))

**Elizabeth Anderson, Evercore ISI** became the loudest post-print UNH bull, raising PT to $400 from $350 (Outperform). She is "taking a long-term view" and believes the "turnaround of the company will be successful," arguing Q1 "supports our turnaround thesis" (thefly.com, April 21, 2026).

**John Ransom, Raymond James** added the nuance on UNH guidance: "Despite the strong quarter, management appears to have absorbed much of the upside through higher costs, and guidance is viewed as conservative, suggesting the market may be expecting a stronger earnings baseline later in the year even as the forward multiple has already risen from recent lows." (PT raised to $370 from $330, Outperform, April 22, 2026)

**Salveen Richter, Goldman Sachs** is the biotech bull cycle caller: "The biotech recovery will persist through 2026 due to vastly improving fundamentals and a highly constructive regulatory environment." ([Zacks](https://www.zacks.com/featured-articles/381/best-biotech-stocks))

**Chris Carabedian, Paul Matteis, Adam Feuerstein** on Biotech Hangout gave ground-level color on the IPO window, covering Kailera, Obsidian Therapeutics' reverse merger with Galera ($350M PIPE), and framing LLY's $300M Crossbridge Bio deal as "Big Pharma is using its massive obesity cash reserves to buy up early-stage pipelines" ([Episode 180, April 17, 2026](https://podcasts.apple.com/gb/podcast/episode-180-april-17-2026/id1568911820?i=1000762071021)).

**Tyler Radke, Citigroup & Adam Hotchkiss, Goldman Sachs on VEEV** drove the week's most dramatic sell-side pivot. Radke downgraded Veeva to Neutral, **slashing PT from $291 to $176**. Hotchkiss initiated at Sell/$215 citing inability to maintain low-to-mid teens growth as key products mature and Salesforce competition intensifies ([Investing.com](https://ca.investing.com/news/analyst-ratings/goldman-sachs-downgrades-veeva-systems-stock-rating-to-sell-on-growth-concerns-93CH-4398819)).

**Matthew Herper & Adam Feuerstein, STAT** reported Andrew Baum's departure from Pfizer: "Andrew Baum, a former analyst at Citi who joined Pfizer in June 2024 to redirect its strategic approach, has left his role as an executive vice president and chief strategy and innovation officer… He will continue as an adviser to Pfizer CEO Albert Bourla until the end of the year." ([STAT, April 20, 2026](https://www.statnews.com/2026/04/20/andrew-baum-pfizer-leaves-post/))

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 3. The Key Debates

### Debate 1: Is UnitedHealth's "turnaround" real, or a dead-cat bounce priced for perfection?

**Bulls** point to the Q1 MCR swing (83.9% vs. ~89% in 2025), the 9% post-print pop, a disciplined "margin over membership" pivot (UNH shed ~80,000 employer/individual members), and a $3B AI investment targeting $1B in operating cost reductions in 2026 alone. "An AI algorithm is entirely dependent on the data it consumes. If you have patient files scattered across 18 different software languages, an AI trying to read that data is just going to hallucinate or break. By forcing everyone onto three standardized systems, UNH's new AI tools can suddenly ingest, analyze, and automate millions of patient files globally at lightning speed." ([Deep Values, April 22, 2026](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f)) Morgan Stanley kept UNH as Top Pick and Evercore, Piper Sandler, Raymond James, and Wells Fargo all raised PTs.

**Bears** point to the two active DOJ investigations (criminal upcoding plus antitrust on UNH/Optum vertical integration), the intrinsic-value gap ("The chasm between the market asking price of $314 and the intrinsic business value of $204 represents a complete lack of a margin of safety" per [Deep Values, April 22, 2026](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f)), and Baird's lingering Underperform at $287 citing Optum Insight weakness. Michael Burry **fully exited** his position per the podcast analysis: "He looked at the 11% returns, looked at the $314 price tag, looked at the risks, and he completely exited his position. He determined the risk-to-reward ratio was entirely broken." ([Deep Values, April 22, 2026](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f)) CMS only proposed a 0.09% 2027 MA rate increase vs. analyst expectations of 4–6% ([Benzinga](https://www.benzinga.com/analyst-stock-ratings/price-target/26/04/52022608/hca-healthcare-earnings-are-imminent-these-most-accurate-analysts-revise-forec)).

### Debate 2: Does Eli Lilly's Foundayo oral GLP-1 launch justify the ~40–45x forward multiple?

**Bulls** argue "The bull case is anchored by the rollout of Foundayo (orforglipron), LLY's newly FDA-approved once-daily oral GLP-1 weight-loss pill that removes needle barriers and began shipping in early April 2026… Bulls argue this targets entirely new, needle-averse demographics" with consensus modeling "a massive 43% year-over-year EPS growth for FY26, with consensus targets ranging from $1,150 to over $1,209" ([TIKR](https://www.tikr.com/blog/eli-lilly-stock-is-down-13-in-2026-does-foundayo-change-the-math)). Guggenheim raised PT to $1,183 (from $1,163) ahead of the April 30 print (thefly.com, April 22, 2026).

**Bears** highlight three pressure points: (1) "Analysts note the stock's massive premium (trading at ~40x to 45x forward P/E) leaves zero margin for error. Bears argue that aggressive pricing pressures from the Trump administration, looming 2026 pharmaceutical tariffs, and heavy capex requirements for manufacturing expansion will drag down margins" ([Morningstar](https://www.morningstar.com/stocks/ahead-earnings-is-eli-lilly-stock-buy-sell-or-fairly-valued)); (2) the CVS Medicare obesity-drug coverage decision, "Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) are under pressure on Tuesday after CVS Health (CVS) announced the company's decision regarding Medicare obesity drug coverage" (thefly.com, April 21, 2026); (3) a shifting podcast narrative, with The Readout LOUD discussing obesity researchers' emerging approach to "literally 'drop GLP-1 as a target' and search for novel mechanisms and successors that could yield better muscle-sparing or tolerability profiles" ([iHeart](https://www.iheart.com/podcast/256-the-readout-loud-31050812/)).

### Debate 3: Is AbbVie's Skyrizi franchise vulnerable to J&J's Icotyde?

**Bears** worry J&J's **Icotyde** launch will erode Skyrizi share in inflammatory bowel disease. Piper Sandler cut ABBV PT to $294 from $299 but defended: "The worry on AbbVie… is driven in part by the rollout of oral IL-23-directed treatment Icotyde by Johnson & Johnson in the psoriasis setting, and how it could impact the trajectory of Skyrizi. Piper would expect that Icotyde will likely expand the overall footprint of the IL-23 category; Skyrizi penetration in inflammatory bowel disease is still quite low." (thefly.com, April 23, 2026). Guggenheim **raised its JNJ Icotyde peak revenue estimate to $14.9B from ~$10B**, lifting PT to $266 (thefly.com, April 20, 2026).

**Bulls** on ABBV: Canaccord initiated Buy/$262: "AbbVie should be a core holding for large-cap biopharma investors. The company has a 'solid and visible' growth profile with a 'best-in-class' Immunology franchise and 'underappreciated' neuro franchise. Canaccord also sees optionality on AbbVie's oncology pipeline" (thefly.com, April 21, 2026).

### Debate 4: Does Merck's LITESPARK-012 miss open the door for Arcus, or simply reset HIF-2α expectations?

Merck and Eisai announced that "the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma did not meet the dual primary endpoints of progression-free survival and overall survival." BofA called the outcome "a major surprise given encouraging phase 2 data" (thefly.com, April 21, 2026).

**Bulls on Arcus (RCUS)** point to H.C. Wainwright: "Merck's study miss could be a positive outcome for casdatifan, saying the drug may now be the only HIF-2α inhibitor to be marketed in the indication should its Phase 3 data be positive." Keeps Buy/$32 PT (thefly.com, April 21, 2026). **Bears** on the HIF-2α class broadly read the Merck miss as a sign the mechanism may be harder to translate than hoped.

### Debate 5: Most Favored Nation pricing, mortal threat or policy theater?

Health Affairs ran multiple episodes this week on regulation. A key episode examined the **"Most Favored Nation" drug pricing policy, a proposal favored by the Trump administration to align US drug launch prices with international markets. Analysts debated its potential chilling effect on global pharmaceutical innovation and venture capital investment"** ([Health Affairs](https://www.healthaffairs.org/podcasts)). The same podcast unpacked the **proposed FY 2027 HHS budget, outlining "major cuts to health agencies and research programs under the 'Make America Healthy Again' initiative, forcing biotech firms to rely more on private capital rather than federal grants"** ([Health Affairs](https://www.healthaffairs.org/podcasts)).

---

## 4. Hot Topics Under Debate

- **Kailera's IPO and the open window.** Biotech Hangout called out "multiple other new filings that signal a highly receptive environment for public debuts" alongside Kailera pricing high and raising **over $625 million**. Obsidian Therapeutics went public via reverse merger with Galera plus a **$350M PIPE** ([Episode 180](https://podcasts.apple.com/gb/podcast/episode-180-april-17-2026/id1568911820?i=1000762071021)).

- **Revolution Medicines' "unprecedented" pancreatic cancer data.** The Readout LOUD reporters called the Phase 3 data "unprecedented" ([iHeart](https://www.iheart.com/podcast/256-the-readout-loud-31050812/)).

- **Allogene CAR-T, "mixed stock reaction" vs. science narrative.** The Readout LOUD interviewed Allogene CMO Zach Roberts; Biotech Hangout analysts debated how the market "is pricing in long-term commercial viability against legacy treatments" ([Episode 180](https://podcasts.apple.com/gb/podcast/episode-180-april-17-2026/id1568911820?i=1000762071021)).

- **Eli Lilly M&A cadence.** LLY is "in advanced discussions to acquire Kelonia Therapeutics for over $2B… The deal price could include additional consideration if specific milestones are reached" ([Lauren Thomas, WSJ, April 19, 2026](https://www.wsj.com/tech/biotech/eli-lilly-nears-deal-for-cancer-biotech-db07be72)). Separately, LLY also added Crossbridge Bio ($300M) and Centessa (CNTA). Guggenheim flagged an IPR&D charge of **$584M, representing 52c to EPS** for Q1.

- **Hims & Hers / LillyDirect partnership.** "Hims & Hers (HIMS) announced access to Eli Lilly (LLY) GLP-1 products through its platform, expanding its weight-loss offering, though its exact role and profit share in the arrangement remains unclear beyond required membership participation" (Leerink, Market Perform, thefly.com, April 23, 2026).

- **Cochlear (COH) fair value cut by 51%.** Shane Ponraj, CFA at Morningstar Australasia cut fair value to AUD 110 after COH cut FY net profit guidance by 23% and shares plunged 41%. Adult cochlear implants are "increasingly being treated as discretionary items; sales are hitting a wall due to severe cost-of-living pressures in the U.S. and crippling hospital capacity constraints across Europe" ([Morningstar](https://www.morningstar.com.au/stocks/we-cut-our-fair-value-estimate-half-this-troubled-healthcare-stock)).

- **Healthcare Services Group (HCSG) 22% surge.** Q1 EPS of $0.37 vs. $0.22 estimate (+68%). Management highlighted "excellent cost controls, enhanced liquidity from a restructured $300M credit facility, and an aggressive continuation of their 75-million-share buyback program" ([Investing.com](https://www.investing.com/news/transcripts/earnings-call-transcript-healthcare-services-q1-2026-beats-eps-forecast-93CH-4629464)).

- **Veeva's 40%-off sell-side pivot.** Contrarian bull: Zacks upgraded VEEV to Strong Buy late in the week; Morgan Stanley's Stan Zlotsky maintains a $350 upside, citing "14 of the top 20 global pharma companies… still firmly transitioning to Veeva's Vault CRM, providing a highly sticky, recurring revenue base" ([TickerNerd](https://tickernerd.com/stock/veev-forecast/)).

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 5. Emerging Themes to Watch

- **"Margin over membership" goes sector-wide.** UNH's deliberate shedding of 80,000 employer/individual members, "You cannot grow your way out of structural unprofitability. Surviving this perfect storm required a ruthless pivot away from their decade-long strategy of grabbing market share at all costs" ([Deep Values, April 22, 2026](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f)), is likely to be mirrored by HUM, ELV, and CNC. Watch Q1 commentary.

- **The provider/payer split.** "Healthcare services have emerged as the clear winner in Q1 2026… In contrast, managed healthcare and insurance experienced a brutal quarter" ([Benzinga](https://www.benzinga.com/analyst-stock-ratings/price-target/26/04/52022608/hca-healthcare-earnings-are-imminent-these-most-accurate-analysts-revise-forec)). HCA, THC, DVA are set up favorably into earnings; insurers face the 0.09% 2027 MA rate increase.

- **IRA Part D is still digesting.** "Under the old rules, once a patient's medication costs hit a certain catastrophic threshold, the federal government stepped in and footed the vast majority of the bill for those ultra-expensive drugs… But the IRA flipped that dynamic. It structurally shifted a massive portion of that financial risk away from the government and directly onto the payers, like UnitedHealthcare. Suddenly, their safety net was gone, and they were on the hooks for those high-tier costs." ([Deep Values, April 22, 2026](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f)) Implication: managed care formularies will keep tightening.

- **Post-GLP-1 science.** The Readout LOUD flagged that obesity researchers are exploring successor mechanisms, muscle-sparing and better tolerability. Potential long-term risk to incumbents' terminal value assumptions.

- **AI as payer-side tool, not just pharma drug discovery.** UNH's 18-to-3 EMR consolidation is the operational precondition, "That is where that billion dollars in savings originates" ([Deep Values, April 22, 2026](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f)). Expect rivals to reveal similar stack rationalizations.

- **Tariff overhang building.** Section 232 tariff regime (100% base duty on imported patented pharmaceuticals effective July 31, 2026) and Section 301 recommendations due July 24, 2026 are underappreciated in bull models. Boston Scientific already took "$200 million in tariff headwinds" in Q1 ([247WallSt](https://247wallst.com/investing/2026/04/21/wall-street-refuses-to-blink-2-healthcare-stocks-at-52-week-lows-that-analysts-still-love/)).

- **Biotech IPO to generalist rotation.** Biotech Hangout argues "the sector is seeing a renewed influx of 'generalist' investors who are returning to biotech after years of sitting on the sidelines" ([Episode 180](https://podcasts.apple.com/gb/podcast/episode-180-april-17-2026/id1568911820?i=1000762071021)).

---

## 6. Stocks on the Radar

| Ticker | Direction | Rationale |
| --- | --- | --- |
| **UNH** | Mixed / Bullish consensus | Q1 beat (EPS $7.23 vs. $6.61), FY26 EPS raised to "greater than $18.25"; Evercore PT $400, Morgan Stanley Top Pick, Raymond James $370; Baird stays Underperform $287; DOJ investigations + CMS rate pressure loom. Buffett holding, Cohen added, Burry exited per [Deep Values](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f). |
| **LLY** | Mixed, leaning Bullish into print | Foundayo launched early April; Guggenheim PT $1,183; Q1 on April 30 with ~43% YoY EPS growth expected. Bears cite 40–45x forward, tariffs, CVS Medicare decision. $2B+ Kelonia deal pending. |
| **NVO** | Bearish | Under pressure with LLY on CVS Medicare obesity decision (thefly.com, April 21, 2026). |
| **UNH vs. HUM/ELV/CNC** | Sector rotation bullish UNH | UNH is best-positioned bellwether; smaller MA-exposed plays face asymmetric downside on 0.09% rate update. |
| **HCA, THC, DVA** | Bullish | Provider tape "clear winner in Q1 2026" ([Benzinga](https://www.benzinga.com/analyst-stock-ratings/price-target/26/04/52022608/hca-healthcare-earnings-are-imminent-these-most-accurate-analysts-revise-forec)); Mizuho raised HCA PT to $585, UBS to $635, JPMorgan to $535 ahead of April 24 print. |
| **MRK** | Bearish near-term | LITESPARK-012 miss; BofA calls it "a major surprise" (thefly.com, April 21, 2026). |
| **RCUS** | Bullish | H.C. Wainwright: casdatifan may now be only HIF-2α inhibitor to market if Phase 3 positive. Buy/$32 PT. Offset: Gilead collaboration ending (Leerink keeps Outperform, PT cut to $47 from $49). |
| **ABBV** | Mixed | Canaccord initiates Buy/$262; Piper $294 (down from $299); Icotyde (JNJ) competitive concern on Skyrizi in IBD. |
| **JNJ** | Bullish fundamentals, Bear GAAP optics | Q1 revenue $24.1B (+9.9%); 64th annual dividend hike; Icotyde ramping. But "Q1 2026 net earnings halved YoY, dropping from $10.9B to $5.2B, weighed down by $300 million in ongoing talc-litigation charges" ([SimplyWall.st](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/what-johnson-johnson-jnjs-q1-revenue-gain-and-64th-straight)). |
| **PFE** | Bearish / Uncertain | Andrew Baum departure, strategic vacuum at the top ([STAT](https://www.statnews.com/2026/04/20/andrew-baum-pfizer-leaves-post/)). Thin news flow otherwise. |
| **GILD** | Neutral | Arcus collaboration wind-down; Leerink not surprised, keeps Outperform (thefly.com, April 20, 2026). |
| **AXSM** | Binary Bullish | April 30 PDUFA on AXS-05 for Alzheimer's agitation ([MarketBeat](https://www.marketbeat.com/instant-alerts/)). |
| **RVMD** | Bullish | "Unprecedented" Phase 3 pancreatic cancer data per The Readout LOUD ([iHeart](https://www.iheart.com/podcast/256-the-readout-loud-31050812/)). |
| **ALLO** | Mixed | Biotech Hangout analysts noted "mixed stock reaction" to latest off-the-shelf CAR-T data ([Episode 180](https://podcasts.apple.com/gb/podcast/episode-180-april-17-2026/id1568911820?i=1000762071021)). |
| **HIMS** | Bullish short-term | LillyDirect partnership, Leerink Market Perform; "likely to support the stock in the near term" (thefly.com, April 23, 2026). |
| **VEEV** | Bearish (Street capitulating) | Citi to Neutral ($291 to $176); Goldman initiates Sell/$215. Contrarian bull: Zacks #1; Morgan Stanley $350 ([Investing.com](https://ca.investing.com/news/analyst-ratings/goldman-sachs-downgrades-veeva-systems-stock-rating-to-sell-on-growth-concerns-93CH-4398819)). |
| **BSX** | Bullish consensus despite pullback | $194M litigation + $200M tariff charges pulled stock to $60s; 10 Strong Buy + 22 Buy, targets up to $124 ([247WallSt](https://247wallst.com/investing/2026/04/21/wall-street-refuses-to-blink-2-healthcare-stocks-at-52-week-lows-that-analysts-still-love/)). |
| **ABT** | Bullish consensus despite pullback | $21B Exact Sciences deal dilutes 2026 EPS by $0.20; FreeStyle Libre +13.8%; 6 Strong Buy + 16 Buy, targets to $143 ([247WallSt](https://247wallst.com/investing/2026/04/21/wall-street-refuses-to-blink-2-healthcare-stocks-at-52-week-lows-that-analysts-still-love/)). |
| **HCSG** | Bullish | Q1 EPS $0.37 vs. $0.22 estimate; +22% on the day ([Investing.com](https://www.investing.com/news/transcripts/earnings-call-transcript-healthcare-services-q1-2026-beats-eps-forecast-93CH-4629464)). |
| **COH (ASX)** | Bearish | Morningstar cut FV 51% to AUD 110 ([Morningstar](https://www.morningstar.com.au/stocks/we-cut-our-fair-value-estimate-half-this-troubled-healthcare-stock)). |

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 7. Upcoming Catalysts (Next ~2 Weeks)

| Date | Ticker / Event | Detail |
| --- | --- | --- |
| **April 24, 2026** | HCA Healthcare Q1 earnings | Mizuho PT $585, UBS $635, JPM $535 ([Benzinga](https://www.benzinga.com/analyst-stock-ratings/price-target/26/04/52022608/hca-healthcare-earnings-are-imminent-these-most-accurate-analysts-revise-forec)) |
| **April 30, 2026** | LLY Q1 earnings | Consensus ~43% YoY EPS growth; IPR&D charge of $584M (52c EPS) disclosed; Guggenheim PT $1,183 |
| **April 30, 2026** | AXSM PDUFA (AXS-05) | FDA decision on Auvelity for Alzheimer's disease agitation |
| **Week of Apr 28** | ABBV earnings | Piper $294, Canaccord $262 (Buy initiation) |
| **Pending** | Dr. Reddy's (RDY) Canada semaglutide approval | "Six to nine months of no competition in the Canadian market" if approved first ([CNBC-TV18, April 23, 2026](https://www.cnbctv18.com/market/dr-reddys-laboratories-share-price-key-trigger-canada-approval-semaglutide-market-size-competition-timeline-19891766.htm)) |
| **July 24, 2026** | Section 301 recommendations due | Medical manufacturing "structural excess capacity" |
| **July 31, 2026** | Section 232 pharmaceutical tariff regime | 100% base duty on imported patented pharmaceuticals |

---

## 8. The Bottom Line

This is a week where the **sector's two halves diverged sharply**. On one side, biotech is enjoying post-pandemic highs, a reopened IPO window (Kailera's $625M+ raise), and legitimately impressive data (Revolution Medicines' "unprecedented" pancreatic cancer readout). On the other side, the managed care model is being stress-tested simultaneously by IRA risk-shift, CMS's 0.09% MA rate update, and two DOJ investigations, yet **UNH's Q1 print came in strong enough that the Street (Evercore, Morgan Stanley, Raymond James, Piper) still raised PTs**. The LLY setup into April 30 is the week's most consequential single-name event: bulls have orforglipron plus ~43% EPS growth; bears have 45x forward, tariffs, and a CVS Medicare headwind. MRK's LITESPARK-012 miss is a reminder that a stock-specific pipeline event can still break a thesis even in a bull tape. Net: constructive on biotech breadth and provider names; watching UNH's regulatory overhang closely; treating LLY's print as the sector's pivot point.

### Data Gaps & Limitations

- **Podcast coverage was heavily skewed to UNH.** Of 492 podcast episodes scanned, only one substantive healthcare stock episode surfaced directly in the matching run (the UNH Deep Values deep dive). Secondary podcast coverage came via web-search summaries of Biotech Hangout, The Readout LOUD, Beyond Biotech, and Health Affairs. We did not capture direct audio of named buyside PMs this week.

- **News gaps:** searches returned no results for **XLV, XBI, AMGN, and BMY** over the 7-day window. PFE news was thin (one item). This newsletter used web and sector-level coverage to backfill.

- **Some tariff/policy dates** (Section 232 effective July 31, 2026; Section 301 recommendations due July 24, 2026) came from contextual notes rather than primary source URLs.

- **No Form 4 / insider, short interest, or 13F data** is included; the covered data set does not include these.

Compiled from podcast, news, and web search runs on April 24, 2026. All quotes verbatim; all citation links preserved from source outputs.

---

## Sources

- [Deep Values UNH deep dive, April 22, 2026](https://app.matterfact.com/podcasts/86e92951d7b0355910db747d89a73e23942c783972fabc7c910c0d5473a8173f)
- [Biotech Hangout, Episode 180, April 17, 2026](https://podcasts.apple.com/gb/podcast/episode-180-april-17-2026/id1568911820?i=1000762071021)
- [The Readout LOUD](https://www.iheart.com/podcast/256-the-readout-loud-31050812/)
- [Health Affairs podcasts](https://www.healthaffairs.org/podcasts)
- [A UnitedHealth reckoning still looms, WSJ](https://www.wsj.com/health/healthcare/a-unitedhealth-reckoning-still-looms-0f094b9b)
- [Eli Lilly nears deal for cancer biotech, WSJ](https://www.wsj.com/tech/biotech/eli-lilly-nears-deal-for-cancer-biotech-db07be72)
- [Andrew Baum leaves Pfizer post, STAT](https://www.statnews.com/2026/04/20/andrew-baum-pfizer-leaves-post/)
- [HCA Healthcare earnings preview, Benzinga](https://www.benzinga.com/analyst-stock-ratings/price-target/26/04/52022608/hca-healthcare-earnings-are-imminent-these-most-accurate-analysts-revise-forec)
- [Eli Lilly and Foundayo, TIKR](https://www.tikr.com/blog/eli-lilly-stock-is-down-13-in-2026-does-foundayo-change-the-math)
- [Is Eli Lilly stock buy, sell, or fairly valued, Morningstar](https://www.morningstar.com/stocks/ahead-earnings-is-eli-lilly-stock-buy-sell-or-fairly-valued)
- [Best biotech stocks, Zacks](https://www.zacks.com/featured-articles/381/best-biotech-stocks)
- [Goldman Sachs downgrades Veeva, Investing.com](https://ca.investing.com/news/analyst-ratings/goldman-sachs-downgrades-veeva-systems-stock-rating-to-sell-on-growth-concerns-93CH-4398819)
- [Veeva forecast, TickerNerd](https://tickernerd.com/stock/veev-forecast/)
- [Healthcare Services Q1 2026 earnings call, Investing.com](https://www.investing.com/news/transcripts/earnings-call-transcript-healthcare-services-q1-2026-beats-eps-forecast-93CH-4629464)
- [Cochlear fair value cut, Morningstar Australasia](https://www.morningstar.com.au/stocks/we-cut-our-fair-value-estimate-half-this-troubled-healthcare-stock)
- [Johnson & Johnson Q1 revenue gain, SimplyWall.st](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/what-johnson-johnson-jnjs-q1-revenue-gain-and-64th-straight)
- [Two healthcare stocks at 52-week lows analysts still love, 247WallSt](https://247wallst.com/investing/2026/04/21/wall-street-refuses-to-blink-2-healthcare-stocks-at-52-week-lows-that-analysts-still-love/)
- [AXSM PDUFA alert, MarketBeat](https://www.marketbeat.com/instant-alerts/)
- [Dr. Reddy's Canada semaglutide trigger, CNBC-TV18](https://www.cnbctv18.com/market/dr-reddys-laboratories-share-price-key-trigger-canada-approval-semaglutide-market-size-competition-timeline-19891766.htm)

---

---

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```